Terlipressin: vasopressin analog and novel drug for septic shock.
OBJECTIVE
To review and assess available literature on chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical studies, adverse events, drug interactions, and dosing and administration of terlipressin in septic shock.


METHODS
A literature search of MEDLINE (1966-September 2006), International Pharmaceutical Abstracts (1970-September 2006), and Cochrane database (third quarter 2006) was conducted, using key terms of terlipressin, lypressin, triglycyl-lysine vasopressin, hemodynamic support, septic shock, vasopressor, and V1 receptor agonist. Bibliographies of relevant articles were reviewed for additional references.


METHODS
Available English-language literature, including abstracts, animal studies, preclinical studies, clinical trials, and review articles, were examined.


RESULTS
Because of potentially favorable pharmacokinetics versus vasopressin and limited availability of vasopressin in some countries, the effects of terlipressin, a vasopressin analog, have been studied recently for the treatment of septic shock. When administered as a 1-2 mg intravenous dose in patients with septic shock, terlipressin increases mean arterial pressure, urine output, systemic vascular resistance index, pulmonary vascular resistance index, and left and right ventricular stroke work index while decreasing heart rate, cardiac output, lactate, and oxygen delivery and consumption index. It is unclear whether lower doses of terlipressin would produce a similar vasopressor response with fewer cardiopulmonary effects and whether the effects of the drug on oxygen transport indices are detrimental.


CONCLUSIONS
Terlipressin is a promising investigational medication for treatment of septic shock. Small trials have shown terlipressin to have favorable effects on hemodynamics in patients with septic shock refractory to conventional vasopressor treatment. It should be used with extreme caution in patients with underlying cardiac or pulmonary dysfunction. Further studies are needed to verify safety, efficacy, and dosing of terlipressin in patients with septic shock, and its use cannot be recommended in lieu of vasopressin at this time.
Pesaturo
Adam B
AB
Department of Pharmacy Services, Saint Joseph Healthcare, Inc., Lexington, KY, USA.
Jennings
Heath R
HR
Voils
Stacy A
SA
D000818:Animals; D006801:Humans; D008236:Lypressin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D017483:Receptors, Vasopressin / Q000378:metabolism; D012772:Shock, Septic / Q000097:blood / Q000188:drug therapy*; D000077585:Terlipressin; D014667:Vasopressins / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use*
D017483:Receptors, Vasopressin; D014667:Vasopressins; D008236:Lypressin; D000077585:Terlipressin